Prevalence and demographic characteristics of Hodgkin lymphoma in Colombia, according to the Ministry of Health data
Abstract
Introduction: Hodgkin lymphoma accounts for approximately 10% of lymphoma cases. The epidemiology of Hodgkin lymphoma has always been a source of fascination to researchers due to its heterogeneous characteristics. Since 1993 in Colombia, the coverage of health services has been extended, and there is an extensive registry of health care processes through the Social Protection Comprehensive Information System. Objectives was To calculate the prevalence and describe the demographic characteristics of Hodgkin lymphoma in Colombia. Materials and methods: Descriptive cross-sectional study with data from the Comprehensive Social Protection Information System of the Ministry of Health of Colombia between 2015 and 2019. Results: 4,396 cases were identified, and a prevalence of 8.9 per 100,000 inhabitants; of these, 55% are men, with a male:female ratio of 1.2:1, with a higher prevalence in the 75-79 years age group. The departments with the highest prevalence are Risaralda (13.33), Bogotá D.C. (13.30), Boyacá (11.9), Quindío (11.49) and Santander (11.44). Conclusions: The prevalence is higher than that reported in the population-based cancer registries in Brazil (5.2), Colombia (5.4), Argentina (8.4), Portugal (8.4) Spain (11.1), France (12.4), United Kingdom (13.9), Italy (13.9), per 100,000 inhabitants between 2016 and 2020. The possibility is proposed that the differences found are due to the lack of population-based cancer registries in Colombian cities in which there is a higher prevalence of this entity and greater aging of the population.
Keywords: Hodgkin lymphomaepidemiologyColombiaprevalence
References
- Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018; 68(2): 116–132.
- Gérard L, Galicier L, Boulanger E, et al. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. AIDS. 2003; 17(1): 81–87.
- Landgren O, Engels EA, Pfeiffer RM, et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst. 2006; 98(18): 1321–1330.
- Chang KL, Albujar PF, Chen YY, et al. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin's disease occurring in Peru. Blood. 1993; 81(2): 496–501.
- Küppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clin Invest. 2012; 122(10): 3439–3447.
- Wang HW, Balakrishna JP, Pittaluga S, et al. Diagnosis of Hodgkin lymphoma in the modern era. Br J Haematol. 2019; 184(1): 45–59.
- Ministerio de salud C. Cifras de aseguramiento en salud 2020. https://www.minsalud.gov.co/proteccionsocial/Paginas/cifras-aseguramiento-salud.aspx (December 28, 2020).
- Departamento Nacional de Estadítica. Archivo de estimación y proyección de la población nacional, departamental y municipal total por área 1985-2020. Investig Proyecciones Población En Colomb 2019. https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/proyecciones-de-poblacion (December 28, 2020).
- Matsuki E, Younes A. Lymphomagenesis in Hodgkin lymphoma. Semin Cancer Biol. 2015; 34: 14–21.
- Albala C, Vio F, Yáñez M. [Epidemiological transition in Latin America: a comparison of four countries] [Article in Spanish]. Rev Med Chil. 1997; 125(6): 719–727.
- Lin J, Siegartel LR, Lingohr-Smith M, et al. Using health care claims data to assess the prevalence of Hodgkin lymphoma and relapsed or refractory Hodgkin lymphoma in the United States. Clin Ther. 2017; 39(2): 303–310.
- Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network. Br J Cancer. 2015; 112(9): 1575–1584.
- Townsend W, Linch D. Hodgkin's lymphoma in adults. Lancet. 2012; 380(9844): 836–847.
- Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009; 9(1): 15–27.
- Yildirim M, Yildiz M, Kurtoglu E, et al. Epidemiology and histological subtypes of Hodgkin lymphoma in the south-west of Turkey. Gulhane Med J. 2012; 54(3): 216.
- Salati M, Cesaretti M, Macchia M, et al. Epidemiological overview of Hodgkin lymphoma across the Mediterranean Basin. Mediterr J Hematol Infect Dis. 2014; 6(1): e2014048.
- Glaser SL, Clarke CA, Chang ET, et al. Hodgkin lymphoma incidence in California Hispanics: influence of nativity and tumor Epstein-Barr virus. Cancer Causes Control. 2014; 25(6): 709–725.
- MacMahon B. Epidemiology of Hodgkin's disease . Cancer Res. 1966; 26(6): 1189–1201.
- Bartlett NL, Foyi KV. 105.Hodgkin lymphoma. https://www.sciencedirect.com/sdfe/pdf/download/eid/3-s2.0-B9781455728657001053/first-page-pdf (December 28, 2020).
- Fields P, Wrench D. Hodgkin lymphoma. Medicine. 2017; 45(5): 305–310.
- IARC. Estimated number of prevalent cases (5-year) as a proportion in 2020, Hodgkin lymphoma, both sexes, all ages n.d. https://gco.iarc.fr (January 4, 2020).
- National Cancer Institute. SEER Cancer Stat Facts: vulvar cancer. Surveillance, Epidemiol End Results Progr 2020. https://seer.cancer.gov (November 20, 2019).
- Bravo LE, Muñoz N, Sanchez GI, et al. Epidemiology of cervical cancer in Colombia. Colomb Med (Cali). 2012; 43(4): 298–304.
- Pardo C, Cendales R. Incidencia, mortalidad y prevalencia de cáncer en Colombia, 2007-2011. Colomb Med (Cali). 2018; 49(1): 16–22.
